SZUKF Stock Chart & Stats
$40.04
$0.00(0.00%)
At close: 4:00 PM EDT
$40.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$27.38 - $45.30
Previous CloseN/A
Volume405.00
Average Volume (3M)0.00
Market Cap
$1.80B
Enterprise Value$261.68K
Total Cash (Recent Filing)$141.67B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)9.6
Beta0.22
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.53%
Share Statistics
EPS (TTM)545.54
Shares Outstanding72,167,206
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.00
Price to Sales (P/S)0.17
P/FCF Ratio22.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.34
Revenue Forecast (FY)$15.78B
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance SheetNear-zero debt and a large, stable equity base materially reduce financial risk, preserving flexibility to invest in logistics, absorb shocks, and sustain operations. This durable low-leverage profile supports long-term resilience and strategic optionality.
Steady Revenue Growth And Improving ProfitsConsistent mid-single-digit revenue growth paired with multiyear profit improvement indicates structural business momentum and better cost or mix management. This trend supports sustainable earnings potential and increased operating leverage over time.
Scale And Logistics-focused Distribution ModelA high-frequency, scale-driven wholesale model creates durable advantages: logistics expertise, supplier relationships, and inventory infrastructure reduce unit costs and raise switching costs for customers, supporting steady revenue flows in the medical distribution niche.
Bears Say
Volatile Cash GenerationLarge year-to-year swings in operating and free cash flow indicate working-capital sensitivity and inconsistent cash conversion. This reduces predictability for capex, dividends, and M&A, increasing execution risk for multi-quarter strategic plans.
Structurally Thin MarginsLow absolute margins inherent to wholesale distribution limit earnings leverage and make profitability more vulnerable to input cost inflation, reimbursement changes, or competitive pressure, constraining long-term ROE expansion.
Recent Cost Pressure On Operating ProfitsAn EBIT decline despite revenue growth signals potential structural cost or efficiency issues. If persistent, rising operating costs will erode the modest margin base and hinder the company's ability to sustain profit improvements.
Suzuken Co News
SZUKF FAQ
What was Suzuken Co Ltd’s price range in the past 12 months?
Suzuken Co Ltd lowest stock price was $27.38 and its highest was $45.30 in the past 12 months.
What is Suzuken Co Ltd’s market cap?
Suzuken Co Ltd’s market cap is $1.80B.
When is Suzuken Co Ltd’s upcoming earnings report date?
Suzuken Co Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 15 days.
How were Suzuken Co Ltd’s earnings last quarter?
Suzuken Co Ltd released its earnings results on May 14, 2026. The company reported $0.651 earnings per share for the quarter, beating the consensus estimate of $0.382 by $0.269.
Is Suzuken Co Ltd overvalued?
According to Wall Street analysts Suzuken Co Ltd’s price is currently Overvalued.
Does Suzuken Co Ltd pay dividends?
Suzuken Co Ltd pays a Semiannually dividend of $0.369 which represents an annual dividend yield of 2.53%. See more information on Suzuken Co Ltd dividends here
What is Suzuken Co Ltd’s EPS estimate?
Suzuken Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suzuken Co Ltd have?
Suzuken Co Ltd has 72,167,206 shares outstanding.
What happened to Suzuken Co Ltd’s price movement after its last earnings report?
Suzuken Co Ltd reported an EPS of $0.651 in its last earnings report, beating expectations of $0.382. Following the earnings report the stock price went down -5.696%.
Which hedge fund is a major shareholder of Suzuken Co Ltd?
Currently, no hedge funds are holding shares in SZUKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suzuken Co Ltd
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions. Its Pharmaceutical Distribution Business focuses on sourcing a wide array of products, including ethical drugs, diagnostic reagents, medical devices, and other health-related items directly from manufacturers, and then supplying these to healthcare institutions and pharmacies. The Pharmaceutical Manufacturing Business is dedicated to the research, development, production, and commercialization of prescription pharmaceuticals and diagnostic tools, with a particular emphasis on diabetes and kidney-related conditions. Through its Pharmacy Business segment, Suzuken offers services via family pharmacists, works to enhance the efficiency of local pharmacy operations, and provides educational support. The Healthcare-Related Services Business encompasses a variety of support functions, such as contract distribution for manufacturers, the distribution of orphan drugs, and nursing care services. This segment is also involved in the development, manufacturing, and sale of medical equipment, including electrocardiographs, blood pressure monitors, stethoscopes, general medical supplies, and health promotion devices. Furthermore, Suzuken Co., Ltd. publishes medical journals for healthcare professionals and collaborates with Bushu Pharmaceuticals Ltd. to provide specialized contract drug services. The company was established in 1932 and is headquartered in Nagoya, Japan.
Technical Analysis
Alfresa Holdings
―
Medipal Holdings
―
Sundrug Co
―
Sugi Holdings Co
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Ownership Overview
―
Insiders
5.57% Mutual Funds
― Other Institutional Investors
87.57% Public Companies and
Individual Investors